93 related articles for article (PubMed ID: 24663076)
1. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.
Gassó P; Rodríguez N; Mas S; Pagerols M; Blázquez A; Plana MT; Torra M; Lázaro L; Lafuente A
Pharmacogenomics J; 2014 Oct; 14(5):457-62. PubMed ID: 24663076
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.
Magalhães P; Alves G; Fortuna A; Llerena A; Falcão A;
Exp Clin Psychopharmacol; 2020 Oct; 28(5):589-600. PubMed ID: 31750687
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
Bakken GV; Molden E; Hermann M
Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
[TBL] [Abstract][Full Text] [Related]
9. Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
Liu R; Gong C; Tao L; Yang W; Zheng X; Ma P; Ding L
Eur J Pharm Sci; 2015 Nov; 79():13-9. PubMed ID: 26360837
[TBL] [Abstract][Full Text] [Related]
10. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.
Eap CB; Bondolfi G; Zullino D; Savary-Cosendai L; Powell-Golay K; Kosel M; Baumann P
J Clin Psychopharmacol; 2001 Jun; 21(3):330-4. PubMed ID: 11386497
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth.
Wisner KL; Avram MJ; George AL; Abramova TV; Yang A; Caritis SN; Costantine MM; Stika CS
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):100-106. PubMed ID: 38421920
[TBL] [Abstract][Full Text] [Related]
13. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
15. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
LLerena A; Dorado P; Berecz R; González A; Jesús Norberto M; de la Rubia A; Cáceres M
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):25-31. PubMed ID: 12450521
[TBL] [Abstract][Full Text] [Related]
16. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.
Llerena A; Berecz R; Dorado P; de la Rubia A
J Psychopharmacol; 2004 Jun; 18(2):189-93. PubMed ID: 15260906
[TBL] [Abstract][Full Text] [Related]
17. Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
Sun CJ; Li L; Li XY; Zhang WY; Liu XW
Arch Gynecol Obstet; 2018 Jul; 298(1):125-132. PubMed ID: 29789925
[TBL] [Abstract][Full Text] [Related]
18. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
[TBL] [Abstract][Full Text] [Related]
19. Real-world clinical characterization of subjects with depression treated with antidepressant drugs focused on (non-)genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study.
Magalhães P; Alves G; Fortuna A; Llerena A; Falcão A
Exp Clin Psychopharmacol; 2020 Apr; 28(2):202-215. PubMed ID: 31120287
[TBL] [Abstract][Full Text] [Related]
20. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.
Noetzli M; Guidi M; Ebbing K; Eyer S; Zumbach S; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
Ther Drug Monit; 2013 Apr; 35(2):270-5. PubMed ID: 23503455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
